Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “MET Gene Mutation”

62 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 62 results

Testing effectiveness (Phase 2)Ended earlyNCT04030429
What this trial is testing

Crizotinib in c-MET Mutation Metastatic/Recurrent/Persistent Endometrial Cancer

Who this might be right for
Endometrial Cancer Recurrent
National Cheng-Kung University Hospital 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT03778229
What this trial is testing

Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib

Who this might be right for
Carcinoma
AstraZeneca 367
Not applicableLooking for participantsNCT05703516
What this trial is testing

A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea

Who this might be right for
Non-Small-Cell Lung Carcinoma
Novartis Pharmaceuticals 44
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07153770
What this trial is testing

Bozitinib Combined With Chemotherapy as Radical Treatment for Stage IIA-IIIC MET-Altered Non-Small Cell Lung Cancer

Who this might be right for
NSCLCMET Exon 14 MutationMET Activating Mutation
Shanghai Pulmonary Hospital, Shanghai, China 34
Testing effectiveness (Phase 2)Looking for participantsNCT05800340
What this trial is testing

Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC

Who this might be right for
Non-Small Cell Lung CancerRET Driver MutationBRAF V600 Mutation+3 more
Guangdong Provincial People's Hospital 30
Not applicableEnrolling By InvitationNCT07122882
What this trial is testing

Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance

Who this might be right for
Oncogene-addicted Non Small Cell Lung CancerEGFR MutationALK Fusion-positive Solid or CNS Tumors+10 more
Chang Gung Memorial Hospital 40
Testing effectiveness (Phase 2)WithdrawnNCT03240393
What this trial is testing

Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
CarcinomaNon-Small-Cell Lung Cancer
Novartis Pharmaceuticals
Large-scale testing (Phase 3)Looking for participantsNCT05722886
What this trial is testing

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol

Who this might be right for
Haematological MalignancySolid Tumour
Cancer Research UK 825
Early research (Phase 1)UnknownNCT04228406
What this trial is testing

Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy Evaluation of GST-HG161

Who this might be right for
Solid TumorC-Met Mutation-Related Tumors
Fujian Cosunter Pharmaceutical Co. Ltd 62
Large-scale testing (Phase 3)Ended earlyNCT04427072
What this trial is testing

Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 22
Testing effectiveness (Phase 2)Looking for participantsNCT03175224
What this trial is testing

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Who this might be right for
Solid TumorsAdvanced CancerRenal Cancer+15 more
Apollomics Inc. 497
Testing effectiveness (Phase 2)Looking for participantsNCT04322890
What this trial is testing

Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

Who this might be right for
Non Small Cell Lung CancerEGFR Gene MutationALK Gene Mutation+2 more
Hunan Province Tumor Hospital 6,000
Not applicableStudy completedNCT00762268
What this trial is testing

A Trial of SAMe for Treatment-Resistant Bipolar Depression

Who this might be right for
Bipolar DisorderDepressionBipolar Depression
Mclean Hospital 23
Testing effectiveness (Phase 2)Study completedNCT02414139
What this trial is testing

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 373
Large-scale testing (Phase 3)Looking for participantsNCT06988475
What this trial is testing

DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations

Who this might be right for
Solid TumourHaematological MalignancyMalignant Neoplasm+8 more
Cancer Research UK 30
Testing effectiveness (Phase 2)Study completedNCT04084717
What this trial is testing

Study of Crizotinib for ROS1 and MET Activated Lung Cancer

Who this might be right for
Non-squamous Non-small-cell Lung CancerStage IV Non-small Cell Lung CancerROS1 Gene Rearrangement+2 more
University Health Network, Toronto 33
Early research (Phase 1)Study completedNCT01531361
What this trial is testing

Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations

Who this might be right for
Advanced Malignant NeoplasmBRAF Gene MutationMetastatic Malignant Neoplasm+2 more
M.D. Anderson Cancer Center 46
Not applicableStudy completedNCT01091506
What this trial is testing

A Placebo-Controlled Study of Physiologic Effects of L-methylfolate in Schizophrenia Patients

Who this might be right for
Schizophrenia
Pamlab, Inc. 55
Large-scale testing (Phase 3)WithdrawnNCT06093503
What this trial is testing

Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein

Who this might be right for
Non-Small Cell Lung Cancer
AbbVie
Post-approval studies (Phase 4)Study completedNCT05110196
What this trial is testing

Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.

Who this might be right for
Non-Small Cell Lung Carcinoma
Novartis Pharmaceuticals 50
Next Page